ArticleCanadian family physician Medecin de famille canadien2014
Safety of the newer class of opioid antagonists in pregnancy.
Article in Canadian family physician Medecin de famille canadien, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03740243 (Comparison of Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Pharmacological interventions for generalised itching (not caused by systemic disease or skin lesions) in pregnancy.The Cochrane database of systematic reviews · 2016Pooled it
- Article
- Update on the Treatment of Opioid Use Disorders in Pregnancy.Focus (American Psychiatric Publishing) · 2017Review
- Rooming-in care for infants of opioid-dependent mothers: Implementation and evaluation at a tertiary care hospital.Canadian family physician Medecin de famille canadien · 2015Article
- Not antagonist treatment.Canadian family physician Medecin de famille canadien · 2014Article
- Response.Canadian family physician Medecin de famille canadien · 2014Article
- Medications for Opioid Use Disorder: A Guide for Physicians.Missouri medicineReview
Corrections and comments
- Commented on by
- Commented on byResponse.2014
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
questionI have a patient recently confirmed to be 6 weeks pregnant. For the past 6 months she has been treated for an opioid addiction with buprenorphine-naloxone combination. Should I be concerned about her exposure to this drug combination up to this point of the pregnancy? Should I switch her medication to methadone now that she is pregnant? ANSWER: The limited data on buprenorphine exposure during pregnancy show no increased risk of adverse outcomes in the newborn. There are limited data on naloxone exposure during pregnancy; however, oral use is not expected to be associated with an increased risk of adverse pregnancy outcomes. Physicians treating pregnant women or women who become pregnant while they are stable taking buprenorphine-naloxone treatment are advised to continue this treatment but to consider transition to buprenorphine monotherapy.
Indexed as
Identifiers
25022635PMC4096261W2152758964What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.